In the “robust effect” article it says “ Results from the initial 4-week trial demonstrated that treatment with SEP-363856 was associated with significant week 4 improvement in negative symptoms compared to placebo, as assessed by the Brief Negative Symptom Scale (BNSS) total score, and BNSS subscale scores for blunted affect, avolition, anhedonia, asociality, alogia and distress. ” So am I to expect improvement in all these areas ? Or are you unsure ?
I do not know which areas. It might differ between patients.
Sunovian updated phase 3 trials at clinical trials dot gov with new estimated completion dates. The trial estimated completion dates may now be January 2023 for shorter trials. The long trial now estimated till 2024.
Ulotarant phase 3 trials